Pharma firm Innova Captab IPO subscribed 1.40 times on first day of offer

The initial public offer of integrated pharmaceutical company Innova Captab got subscribed 1.40 times on the first day of subscription on Thursday

IPO
The Rs 570 crore initial share sale received bids for 1,27,25,196 shares against 90,78,010 shares on offer, as per NSE data.
Press Trust of India New Delhi
2 min read Last Updated : Dec 22 2023 | 12:25 AM IST

The initial public offer of integrated pharmaceutical company Innova Captab got subscribed 1.40 times on the first day of subscription on Thursday.

The Rs 570 crore initial share sale received bids for 1,27,25,196 shares against 90,78,010 shares on offer, as per NSE data.

The category for Retail Individual Investors (RIIs) received 2.12 times subscription while the quota for non-institutional investors was subscribed 96 per cent. The category for Qualified Institutional Buyers (QIBs) received 44 per cent subscription.

The Initial Public Offer (IPO) has a fresh issue aggregating up to Rs 320 crore and an Offer for Sale of up to 55,80,357 equity shares.

The IPO comes in a price range of Rs 426-448 a share.

Innova Captab on Wednesday said it has collected Rs 171 crore from anchor investors.

Proceeds from fresh issuance worth Rs 144.40 crore will be utilised for payment of debt, Rs 23.60 crore for investment in the subsidiary, UML, Rs 72 crore for funding working capital requirements, besides, a portion will be used for general corporate purposes.

Innova Captab is an integrated pharmaceutical company with a presence across the pharmaceuticals value chain, including research and development, manufacturing, drug distribution, marketing, and exports.

ICICI Securities and JM Financial are the managers to the offer.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :IPO valuationpharmaceutical firmsstock market trading

First Published: Dec 22 2023 | 12:25 AM IST

Next Story